Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
Elgammal, Yehia ; Salama, Ehab A. ; Seleem, Mohamed N. SCI REP-UK,2024,14(1):1571. DOI: 10.1038/s41598-024-52012-8 PubMed ID: 38238403
More
Abstract: The increasing incidence and dissemination of multidrug-resistant Candida auris represents a serious global threat. The emergence of pan-resistant C. auris exhibiting resistance to all three classes of antifungals magnifies the need for novel therapeutic interventions. We identified that two HIV protease inhibitors, atazanavir and saquinavir, in combination with posaconazole exhibited potent activity against C. auris in vitro and in vivo. Both atazanavir and saquinavir exhibited a remarkable synergistic activity with posaconazole against all tested C. auris isolates and other medically important Candida species. In a time-kill assay, both drugs restored the fungistatic activity of posaconazole, resulting in reduction of 5 and 5.6 log10, resp. Furthermore, in contrast to the individual drugs, the two combinations effectively inhibited the biofilm formation of C. auris by 66.2 and 81.2%, resp. Finally, the efficacy of the two combinations were tested in a mouse model of C. auris infection. The atazanavir/posaconazole and saquinavir/posaconazole combinations significantly reduced the C. auris burden in mice kidneys by 2.04- (99.1%) and 1.44-log10 (96.4%) colony forming unit, resp. Altogether, these results suggest that the combination of posaconazole with the HIV protease inhibitors warrants further investigation as a new therapeutic regimen for the treatment of C. auris infections.
Purchased from AmBeed: 198904-31-3 ; 127779-20-8
CAS No. : | 198904-31-3 | MDL No. : | MFCD08435966 |
Formula : | C38H52N6O7 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | AXRYRYVKAWYZBR-GASGPIRDSA-N |
M.W : | 704.86 | Pubchem ID : | 148192 |
Synonyms : |
BMS-232632;CGP 73547;Reyataz;Zrivada;Latazanavir
|
Chemical Name : | 1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
84% | With 4-methyl-morpholine; diisopropyl-carbodiimide; In dichloromethane; isopropyl alcohol; at -10 - 20℃;Inert atmosphere;Product distribution / selectivity; | Example 1 : Preparation of atazanavir using 1 equivalent of compound (II), 3.5 equivalents of compound (III), 3.5 equivalents of DIC, and 6.6 equivalents of NMM97.5 g of 1 -[4-(piridyn-2-yl)phenyl-4(S)-hydroxy]-5-(S)-2,5-diamino-6-phenyl- 2-azahexane trihydrochloride (trihydrochloride of compound (II) with a 10%wt content of isopropanol, 185.97mmol) were suspended into 683 ml of dichloromethane under nitrogen atmosphere at -10 0C. 135 ml_ (1227.40 mmol) of /V-methylmorpholine were added maintaining the temperature at -10 0C.Separately, 100.8 ml_ (650.90 mmol) of N,N-diisopropylcarbodiimide were added to a suspension of 123.2 g (650.90 mmol) of N-(methoxycarbonyl)-L- tert-leucine (compound (III)) into 975 ml of dichloromethane.Then, the first suspension was quickly transferred over the second one. The resulting mixture was warmed up to room temperature and was maintained at such temperature until the reaction was completed (93% atazanavir by HPLC, monoimpurity content: 1.2%). The reaction mixture was filtered off and was washed with 800 ml_ of water. Then, the organic phase was concentrated up to half volume and 500 ml_ of tert-butylmethylether were added. The mixture was concentrated again up to half volume. This operation was repeated three times up to a dichloromethane content equal or less to 20%. The precipitated product was recovered by filtration. 125.4 g of atazanavir were obtained (Yield =96%). Purity by High Performance Liquid Chromatography (HPLC) = 98.2%, with 4% of N,N-diisopropylurea (DIU) and free of the other probable diastereomers. Molar yield =92%. Recrystallization in ethanol/water 45:55 yielded 105.34 g of atazanavir (149.5 mmol). Recrystallization yield: 84%. Purity HPLC = 99.4%, free of DIU, and free of the other probable diastereomers.The formula of the three probable diastereomers and the HPLC conditions to detect their presence are included below:d-ld-ll d-lHPLC conditions:Liquid chromatograph with UV detector equipped with automatic injector, and integration systemColumn: ZORBAX Eclipse XDB-C18 150x4.6 mm, 5mum.Mobile phase: A (0.05% formic acid in water) and B (ACN)Gradient elution:Detection: 254 nmFlow: 1 mL/minColumn temperature: 25 0CInjection: 2 muLTime injection and chromatogram: 20 minRelative retention time of the diastereomers (RRT): |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | With sulfuric acid; In acetone; at 0 - 50℃; for 2h; | Example 2: Preparation of <strong>[198904-31-3]atazanavir</strong> sulfateA compound obtained as in Example 1 was transformed into the sulfate salt by addition of sulfuric acid following the process described in WO 9936404, in order to confirm that no racemization has been occurred following the process of the present invention. The confirmation was done by comparing the rotatory power of the <strong>[198904-31-3]atazanavir</strong> in form of sulfate salt obtained following the process of the present invention with the value known in the state of the art for <strong>[198904-31-3]atazanavir</strong> sulfate.172.8 g (245.16 mmol) of <strong>[198904-31-3]atazanavir</strong> and some crystals of <strong>[198904-31-3]atazanavir</strong> sulfate were suspended in 1728 ml acetone at 50 0C. 49 ml_ of sulfuric acid 5M (245.16 mmol) were quickly added and after a few minutes precipitation of a product was observed. It was maintained first at 50 0C during 1 hour, then at 25 0C during 30 min and, finally, at 0 0C during an additional 30 min. The solid was filtered off, washed with 170 ml_ of acetone and 170 ml_ of heptane, and dried under vacuum. 186.7 g (232.52 mmol) of <strong>[198904-31-3]atazanavir</strong> sulfate were obtained (yield: 95%, purity HPLC: 99.85%). [alpha]D : -45.3 (MeOH/H2O 1 :1 , 1 mg/mL). The rotatory power of <strong>[198904-31-3]atazanavir</strong> sulfate described in the literature is [CC]D : -46.1 (cf. Z. Xu et al., Organic Process Research & Development, 2002, vol. 6, pp. 323-328) which confirms that <strong>[198904-31-3]atazanavir</strong> base or its salts can be obtained by the process of the present invention efficiently without causing racemization. |
95.2% | With sulfuric acid; In ethanol; at 20 - 30℃; | The purity is84.0% 41.9 g(Fold pure 35.2 g, 50.0 mmol) of <strong>[198904-31-3]atazanavir</strong> monomer was dissolved in 175 mL of ethanol,Stir the liquid at 20-30 C until clear and transparent,Poured into 80g containing activated 732 strong acid cation exchange resin column(Diameter 200mm, flow rate 2 ~ 3 drops / second)Dissociation and exchange, until the product is fully adsorbed to the resin, then use aboutThe resin was washed with 200 mL of ethanol and 400 mL of purified water to remove the adherent organic and inorganic impurities that did not adsorb to the resin. The resin column was eluted with 2% dilute sulfuric acid (1.2 L) at 20-30 C before dissociation and exchange (the eluate was detected by TLC until there was no <strong>[198904-31-3]atazanavir</strong> monomer), and the eluate was concentrated to the original volume 1/5 ~ 1/6, at 50 C by adding 0.3 grams of 767-type charcoal charcoal bleaching 20min, filtered, and then heated to the filtrate was added dropwise 200mL acetone, naturally reduced to 20-30 C, and then stirred for 5 ~ 6h, filtered , The filter cake was washed with 15mL acetone to give white powdery solid <strong>[198904-31-3]atazanavir</strong> 38.3g, yield 95.2%, HPLC purity of 99.9% |
94% | With sulfuric acid; pyrographite; In 1,2-dimethoxyethane; dimethyl sulfoxide; at 35℃;Inert atmosphere; | <strong>[198904-31-3]Atazanavir</strong> free base (10 g, 14.19 mmol) was added to a mixed solvent of 150 mL ethylene glycol dimethyl ether and 8 mL DMSO.The temperature was raised in an argon atmosphere, and after the system was dissolved, 0.1 g of activated carbon was added for decolorization (system temperature was 50-60 C.) and filtered to obtain a clear solution.At a controlled temperature of 35 ± 5 C, the prepared clear solution was added dropwise with concentrated sulfuric acid (0.8 mL, 14.4 mmol);After dripping, heat and stir for 1 to 2 hours;Slowly (about 30 to 60 minutes) cool down to 0 to 15C, filter, filter cake is washed with ethylene glycol dimethyl ether 2 or 3 times, vacuum dried at 40 to 60C for 5 to 8 hours,That is, <strong>[198904-31-3]atazanavir</strong> sulfate 10.7g, the molar yield is 94.0%, the HPLC purity is >99.5%, and the maximum single impurity is <0.1%. |
91% | With sulfuric acid; In ethanol; tert-butyl methyl ether; at 20 - 30℃; for 4h; | Example 3: 0.085 mL of sulfuric acid (concentrate, 1.1 equiv) was added into the mixture of 1 g of <strong>[198904-31-3]atazanavir</strong> base, 7.5 mL of EtOH (7.5 vol) and 7.5 mL of MTBE (7.5 vol) at 20-30 C. The resulting clear amber solution was stirred at 20-30 C. for 4 hr. The product was filtered, washed with a mixture of EtOH/MTBE (1:2, 3 mL, 3 vol), and dried under vacuum at 40-50 C. for 16 hr to afford <strong>[198904-31-3]atazanavir</strong> sulfate in Form A (1.04 g, 91% yield, 99.9% HPLC purity). |
87.8% | With sulfuric acid; In methanol; ethyl acetate; at 43℃; for 1h; | Example 2: Preparation of compound (A) using ethyl acetate: methanol A solvent mixture of 500 ml of ethyl acetate and 50 ml of methanol was added to 100 gms of (3S,8S,9S,12S)-3,12- bis(l ,l-dimethylethyl)-8-hydroxy-4,l l-dioxo-9-(phenylmethyl)-6-[[4-(2- pyridinyl) phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester [Compound (II)]. The reaction mixture was stirred at a temperature of 27±2C to get a suspension. The temperature of the suspension was then raised to 43±2C and 7.5 ml (13.9 gms) of sulphuric acid was added slowly. The solution was maintained for an hour at a temperature of 43±2C whereby a solid was obtained. The material was cooled down to a temperature of 27±2C. To this 200 ml of ethyl acetate was added, followed by chilling the reaction mixture at a temperature of 3±2C. The solid obtained was filtered and washed with 1 volume of ethyl acetate. The solid was then exposed to drying process under vacuum at 27±2C for 2 hours. The material was powdered and again exposed to drying process under vacuum (630±20 mm of Hg) at 53±2C for 4 hours. The drying process was continued till the LOD (loss on drying) was less than 0.5%w/w to obtain the title compound. Dry weight: lOOgms Yield: 87.8% HPLC Purity: 99. 9% |
74.3% | With potassium fluoride; sulfuric acid; In ethanol; n-heptane; at 15 - 37℃; for 8.25h; | EXAMPLE 3 <strong>[198904-31-3]Atazanavir</strong> Bisulfate-Form E3 (Triethanol Solvate) <strong>[198904-31-3]Atazanavir</strong> free base (prepared as described in Example 1, Part C) (3.0 g, 4.26 mmol) was slurried in dry, 200 proof ethanol (20.25 mL, 6.75 mL/g of free base) in a 100 mL, 3-neck round-bottom flask fitted with a mechanical stirrer, temperature probe, and a pressure-equalizing liquid addition funnel. Concentrated H2SO4 (0.25 mL, 0.46 g, 4.69 mmol, 1.1 eq.) was added to the slurry of <strong>[198904-31-3]atazanavir</strong> free base which was maintained at 20-25 C. The resulting solution (KF of 0.2 to 1.0% water) was polish filtered (Whatman #1 paper), the filter rinsed with 2.25 mL of absolute ethanol and the rinse added to the filtered solution. The solution was heated to 37 C. and seeded with 10 mg of amorphous <strong>[198904-31-3]atazanavir</strong> bisulfate derived from Form E3 crystals (by exposing Form E3 crystals to ambient temperature), and the mixture was agitated for 15 min. Heptane (380 mL, 8.25 mL/g of free base) was added over 1 hour. The resulting crystallization mixture was agitated for 8 h at 15-25 C. Crystallized <strong>[198904-31-3]atazanavir</strong> bisulfate was filtered on a Buchner funnel. The product cake was washed with 184 mL (4 mL/g of free base) of 1:1 ethanol: heptane. The product cake was washed with 46 mL (1 mL/g of free base) of heptane. The resulting product was dried under vacuum at 40-50 C. until it had an LOD=0.97%. The yield of product was 47.7 g (0.0594 mol, 74.3 mol %) of <strong>[198904-31-3]atazanavir</strong> bisulfate Form E3 (triethanol solvate) with HPLC HI=100.0 (see FIGS. 9 and 10). |
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 20 - 50℃; for 7h; | E. 1-[4-(Pyridin-2-yl)phenyl]-5(S)-2,5-bis [N-(methoxycarbonyl)-L-tert-leucinyl]amino}-4(S)-hydroxy-6-phenyl-2-azahexane bisulfate salt About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) was added to the free base acetone/N-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture was seeded with 5.0 wt % (wrt calculated free base in solution) of bisulfate salt. The seeded mixture was agitated at 40-50 C. for at least 30 minutes during which time the bisulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) was added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage was determined according to the cubic equation described hereinbefore and is shown in the table below. TABLE 1 Stage mL/kg/h mL(H2SO4)/h g(H2SO4)/h Duration (min) 1 4.62 0.579 1.065 60 2 6.93 0.868 1.597 60 3 16.55 2.073 3.814 60 4 30.26 3.790 6.974 60 5 48.47 6.071 11.171 23 After addition of H2SO4 was complete, the slurry was cooled to 20-25 C. for at least 1 h with agitation. The slurry was agitated at 20-25 C. for at least 1 h. The bisulfate salt was filtered and the mother liquor was recycled as needed to effect complete transfer. The filter cake was washed with acetone (5-10 mL/g of free base; 1200 mL acetone). The bisulfate salt was dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material. The crystalline product was analyzed by PXRD, DSC and TGA patterns and SSNMR spectrum and found to be (non-solvated) Form A crystals of the title bisulfate (see FIGS. 1 to 5). | |
With sulfuric acid; In ethanol; at 25 - 30℃; for 0.666667h;Industry scale; | To a solution of <strong>[198904-31-3]atazanavir</strong> base (60 Kg) in ethanol (390 L), concentrated sulfuric acid (5.16 L) was added at 25 - 30C and stirred for 40 minutes. To the solution n-heptane (498 L) and seed of <strong>[198904-31-3]atazanavir</strong> sulfate ( 80 g) were added. Stirred at 25 - 30C for 16 hours. The solid was filtered, washed with 1 : 1 mixture of ethanol: n-heptane and dried to give 58 Kg of <strong>[198904-31-3]atazanavir</strong> sulfate. (HPLC data: <strong>[198904-31-3]atazanavir</strong> sulfate - 99.93%, RSSS isomer - 0.01%, SSSR isomer - 0,01 %, RSSR isomer - below detection limit). | |
With sulfuric acid; In acetone; at 40 - 45℃; | Example 7: Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1 : 1) Formula I To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N- methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2 x 150 mL). The filtrates were combined, heated to 40C to 45C and dichloromethane was recovered atmospherically. Sequentially, acetone (2 x 750 mL) was added to the reaction mass, the solution so obtained was heated to 60C to 65C and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60C to 65C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40C to 45C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40C to 45C and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20C to 25C and stirred for 3 hours to 4 hours at 20C to 25C. The solid was filtered and acetone (1200 mL) was added at 20C to 25C to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45C to 50C to afford the title compound. Yield(w/w): 1.03 | |
Example 7 Preparation of <strong>[198904-31-3]Atazanavir</strong> Bisulfate (1:1) To <strong>[198904-31-3]atazanavir</strong> (150 g; obtained in Example 6), dichloromethane (900 mL) and N-methylpyrrolidine (188 mL) were added under stirring at ambient temperature and further stirred for 30 minutes to 40 minutes. After the solution became clear, activated carbon (7.5 g) was added and further stirred for 30 minutes to 40 minutes at ambient temperature. The reaction mixture was filtered through a hyflo-bed and the bed was washed twice with dichloromethane (2*150 mL). The filtrates were combined, heated to 40 C. to 45 C. and dichloromethane was recovered atmospherically. Sequentially, acetone (2*750 mL) was added to the reaction mass, the solution so obtained was heated to 60 C. to 65 C. and acetone was recovered atmospherically and then vacuum was applied for 30 minutes to 45 minutes at 60 C. to 65 C. After that, acetone (2400 mL) was added at the same temperature and then cooled to 40 C. to 45 C. Concentrated sulfuric acid (22.96 g) was slowly added over a period of 3 hours to 4 hours at 40 C. to 45 C. and stirred for 30 minutes to 40 minutes. The reaction mixture was cooled to 20 C. to 25 C. and stirred for 3 hours to 4 hours at 20 C. to 25 C. The solid was filtered and acetone (1200 mL) was added at 20 C. to 25 C. to the wet cake and stirred for 15 minutes to 20 minutes. The solid was filtered, washed with acetone (150 mL) and dried under vacuum at 45 C. to 50 C. to afford the title compound. | ||
With sulfuric acid; In 1-methyl-pyrrolidin-2-one; acetone; at 40 - 50℃; for 0.5h; | About 10% (2 g) of the total charge of concentrated sulfuric acid (19 g, 1.10 eq.) is added to the free base acetoneN-methylpyrrolidone solution of Part D, while maintaining the temperature at 40-50 C., via subsurface addition. The reaction mixture is seeded with 5.0 wt % (wrt calculated free base in solution) of sulfate salt. The seeded mixture is agitated at 40-50 C. for at least 30 minutes during which time the sulfate salt began crystallizing as evidenced by the mixture increasing in opacity during this time. The remaining sulfuric acid (17.8 g) is added over ca. 5 h in five stages according to the following protocol, defined by a cubic equation, while keeping the temperature at 40-50 C. The rate of each addition stage is determined according to the cubic equation described in U.S. Patent Publication No. U520050256202A1, published Nov. 17, 2005. After addition of H2504 is complete, the slurry is cooled to 20-25 C. for at least 1 h with agitation. The slurry is agitated at 20-25 C. for at least 1 h. The sulfate salt is filtered and the mother liquor is recycled as needed to effect complete transfet The filter cake is washed with acetone (5-10 mEg of free base; 1200 mE acetone). The sulfate salt is dried at NMT 55 C. under vacuum until the LOD<1% to produce a crystalline material. |